大连医科大学附属二院肿瘤内科是辽宁省重点专科、大连市医学重点专科。博士、硕士学位授权点，已培养博士5名，硕士40余名。学科现有教授7人，副教授9人，博士学位7人，硕士学位14人，床位200张。国家抗肿瘤新药临床试验研究基地，大连市化疗质控中心单位。 学科注重临床医疗工作，以肿瘤综合治疗模式为主导，以规范化治疗为方向，率先在东三省实行肿瘤专科治疗的细化，成立了乳腺、胸部、腹部、头颈部及淋巴瘤等专科病房，实现了专病专治；同步建立包括化学治疗、物理治疗、基因治疗、免疫治疗、分子靶向治疗在内的肿瘤综合治疗模式。为了更好的提高肿瘤综合治疗的疗效，2001年省内首家引进射频技术，用于治疗肺癌、肝癌，具有疗效可靠、微创的优势；2003年开展肿瘤介入治疗，治疗消化道肿瘤及肿瘤常见并发症如梗黄、静脉癌栓、消化道梗阻等；将介入治疗与放射治疗的有机结合使一部分食道、胆道恶性肿瘤患者得到有效的治疗；并探索局部晚期乳癌、宫颈癌术前介入化疗等新技术。2006年成立肿瘤配药中心，使肿瘤化疗药物的应用达到国内一流水平；连续承办“肿瘤规范化治疗”方面的国家级教育项目，并在2008年被聘为大连市化疗质控中心单位。作为国家抗肿瘤新药临床试验研究基地，自2000年始共完成60余项II、III期临床试验，包括抗肿瘤化疗药物、基因治疗药物、分子靶向治疗药物等，其中国际多中心临床试验10余项，2005年被SFDA批准为I期临床试验研究基地。 1999年率先在东北地区开展小剂量5-FU持续灌注为基础的联合化学治疗晚期消化系肿瘤的临床研究，较早提出“肿瘤冬眠疗法”、“肿瘤患者带瘤生存”等新观点，并逐渐被广泛接受，并获得大连市科技成果一等奖。2000年12月首先在东北三省开展了多电极射频热凝治疗恶性肿瘤的临床及基础研究，同时成功申报了2项大连市科委课题。2001年以来开展了E1B基因缺陷腺病毒的基因治疗，完成了H101治疗恶性实体肿瘤的II期、III期临床研究，并获得国家高技术研究发展计划863计划项目子课题1项、辽宁省教育厅课题2项、辽宁省科技厅立项1项。之后在抑制肿瘤血管形成研究领域进行了大胆地探索，开展了多项基础及临床研究，获辽宁省科委科技进步三等奖1项。近年来在分子靶向治疗领域开展了靶向药物耐药机制方面的研究探讨，获辽宁省教育厅课题2项。截至目前，获得大连市科委课题5项，辽宁省科委课题4项，辽宁省教委课题3项，大连市新技术应用5项，发表国家级论文50篇，省级论文10篇，会议交流论文20篇。 在新的形势下，学科将进一步强化竞争机制，加强学术交流，通过团队联合申报高层次课题，实施国家重点学科培育计划，以学校本部和医院为依托，计划在不远的将来建设成为国家重点学科。

    Subject introduction

    The Oncology department of the 2th affiliated hospital of DaLian Medical University is the key medical science of DaLian city and LiaoNing province, an authorized doctorship site for M D. The department, which possesses 7 proffessors, 9 associate professors, 7 M D, 14 master and200 bed, is engaged for chemotherapy quality control(QC) unit of DaLian city and national anti-tumour new drug clinical trial department. To follow the combined mode of tumour and to aim standardize therapy, the department make a further demarcation according to body region, set up the breast tumour department, the chest tumour department, the abdomen tumour depart ment, the head and neck tumour department, the lymphoma department, this is a pioneering work in the three provinces in northeast China. The combined therapy mode of tumour, including chemotherapy, physiotherapy, gene therapy, immunotherapy, targeted therapy, was founded synchronously. The radio frequency technique is introduced on 2001, which have some advantages of good focus effect with small wound and are used to cure lung cancer, live cancer, and the interventional therapy is developed on 2003 for some complications with tumour, such as obstructive jaundice, tumour bolt, digestive canal obstruction, etc. The combination of interventional therapy and radiotherapy was effective for some esophagus and biliary tract tumour. New skill was explored for advanced breast cancer, uterine cervix cancer preoperative chemotherapy. The dispensing center of anti-cancer drug was established on 2006, and made the application of anti-cancer drug to advanced level in china. To undertake continuously national education proceeding of “standardize therapy of tumour” and be engaged for chemotherapy quality control(QC) unit of DaLian city on 2008. As national anti-tumour new drug clinical trial department, we have completed 60 II、III stage clinical trials including anti-tumour drug, gene drug, molecule tareted therapy drug,etc and been given approval for I stage clinical trial on 2005 by SFDA. The combined chemotherapy, based on low dose fluorouracil infusion persistently, was firstly used to advanced digestion tumour in the three provinces in northeast China and this research had won technology achivement prize of DaLian city and LiaoNing province. The clinical and fundamantal research about multiple-electrode radio frequence treat malignant tumour was carried on dec/2000 and 2 topic was reported. The gene therapy about E1B gene defect adenovirus was developed from 2001 and had completed II、III stage clinical research about H101 treat malignant solid tumour and won 1 topic of national 863 program, 2 topics of the department of education, 1 topic of the department of technology of LiaoNing province. Many fundamental and clinical research was developed on tumour vessel formation suppression and had won 1 three divisions prize of the department of science. The research, with regard to targeted drug fast mechanism on molecule targeted therapy, had won 2 topics of the department of education of LiaoNing province. By now, the department have won 1 topic of national 863 program, 9 topics of LiaoNing province, 10 topics of DaLiam city, and published 50 national level essaies, 30 provincial level essaies, 20 articles for conference communication. The lead of subject is prof. ZhangYang, whose research direction is combined therapy of malignant tumour. We will further strengthen competition mechanism, increase academic interchange, report to higher topics, hold university and hospital and build national key subject.